Quarterly ResultAug 5, 2026, 07:26 AM
Lifecore Biomedical Q2 Net Loss Widens to $(6.16)M
AI Summary
Lifecore Biomedical, Inc. reported a widened net loss for the second quarter of 2026, reaching $(6.16) million, up from $(1.15) million in the prior year. Total revenues for the quarter decreased to $34.17 million. Despite the challenging financial performance, the company announced positive developments regarding legal matters, including the conclusion of an SEC investigation with no action taken and preliminary court approval for a class action lawsuit settlement. The company's total liabilities increased to $213.41 million as of June 30, 2026.
Key Highlights
- Q2 2026 total revenues decreased to $34.17 million from $36.44 million year-over-year.
- Q2 2026 net loss widened to $(6.16) million from $(1.15) million year-over-year.
- Q2 2026 loss per share increased to $(0.19) from $(0.06) year-over-year.
- Six-month net loss increased to $(21.14) million from $(15.92) million year-over-year.
- SEC investigation concluded with no action taken against Lifecore Biomedical.
- Class action lawsuit settlement received preliminary court approval.
- Total liabilities increased to $213.41 million from $198.12 million since December 31, 2025.
- Cash and cash equivalents stood at $17.24 million as of June 30, 2026.
Price Impact
More from LFCR